| Stage | CAH | % of rev | COR | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $63.7B | 100.00% | $84.8B | 100.00% | COR ×1.33 |
| Gross profit | $2.6B | 4.02% | $3.6B | 4.26% | COR +0.2pp |
| Operating income | $729M | 1.14% | $1.1B | 1.32% | COR +0.2pp |
| Pre-tax income | $554M | 0.87% | $996M | 1.18% | COR +0.3pp |
| Net income | $400M | 0.63% | $777M | 0.92% | COR +0.3pp |
| Stage | CAH | COR | Gap · A − B |
|---|---|---|---|
| Revenue | $63.7B100.00% | $84.8B100.00% | COR ×1.33 |
| Gross profit | 4.02%$2.6B | 4.26%$3.6B | COR +0.2pp |
| Operating income | 1.14%$729M | 1.32%$1.1B | COR +0.2pp |
| Pre-tax income | 0.87%$554M | 1.18%$996M | COR +0.3pp |
| Net income |
| 0.63%$400M |
| 0.92%$777M |
| COR +0.3pp |
CAH · CTXR 10-KDec 23 '25
“LYMPHIR, Citius Oncology has entered into distribution agreements with Cardinal Health, Cencora and McKesson Corporation.”
COR · CTXR 10-KDec 23 '25
“LYMPHIR, Citius Oncology has entered into distribution agreements with Cardinal Health, Cencora and McKesson Corporation.”